News
Effective 1/30/20: Texas Medicaid Preferred Drug List Updates
Date: 01/03/20
Superior HealthPlan follows the Texas Medicaid Vendor Drug Formulary and the Preferred Drug List. On, January 27, 2020, the Texas Health and Human Services Commission (HHSC) will publish the semi-annual update of the Texas Medicaid Preferred Drug List (PDL), effective January 30, 2020. The update will be based on changes presented at the Vendor Drug Program (VDP) Drug Utilization Review (DUR) Board meetings in July and October 2019.
The tables below summarizes some of the anticipated noteworthy changes from the July 2019 and October 2019 DUR meetings.
Please note: The tables are not the complete list of changes. Please reference the Texas Medicaid Preferred Drug List for a complete list of recommended medications or visit the Texas Vendor Drug website for all the DUR board decisions.
Notable changes from July 2019 DUR board meeting:
Drug Name |
Current Status |
Recommended Status |
|---|---|---|
Inbrija (Inhalation) |
No status |
Non-Preferred |
Cefprozil Tablets (Oral) |
Non-Preferred |
Preferred |
Nivestym Vial (Injection) |
No Status |
Non-Preferred |
Skyrizi (Subcutaneous) |
No Status |
Non-Preferred |
Tremfya Auto-injector (Subcutaneous) |
No Status |
Non-Preferred |
Motegrity (Oral) |
No Status |
Non-Preferred |
Ofloxacin (Ophthalmic) |
Non-Preferred |
Preferred |
Rocklatan (Ophthalmic) |
No Status |
Preferred |
Hydroxyprogesterone Caproate (Intramuscular) |
No Status |
Non-Preferred |
Canasa (Rectal) |
Preferred |
Non-Preferred |
Lialda (Oral) |
Preferred |
Non-Preferred |
Mesalamine (Rectal) |
Non-Preferred |
Preferred |
Notable changes from October 2019 PDL DUR meeting:
Drug Name |
Current Status |
Recommended Status |
|---|---|---|
Sklice (Topical) |
Preferred |
Non-Preferred |
Humulin 500,70/30, Pen (OTC) |
Non-Preferred |
Preferred |
Humalog Pen,Mix Pen, Junior Kwikpen, Cartridge |
Non-Preferred |
Preferred |
Novolin Vial |
Non-Preferred |
Preferred |
Buprenorphine/Naloxone (Tablets and Film), Lucemyra |
Non-Preferred |
All agents in this class are preferred |
Saphris (Sublingual) |
Preferred |
Non-Preferred |
Udenyca (Subcutaneous) |
Non-Preferred |
Preferred |
Cosentyx pen injecter (Subcutaneous) Cosentyx syringe (Subcutaneous) |
Preferred |
Non-Preferred |
Rinvoq ER (Oral) |
Not Rated |
Non-Preferred |